Clinical trials
Peritoneal Metastases From Colorectal Cancer clinical trials
Below are recruiting peritoneal metastases from colorectal cancer clinical trials, each written for real people, not researchers. We’re tracking 63 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06783491RecruitingPhase 3
Chemotherapy with or without heated chemo for advanced colon cancer
This trial tests if adding heated chemotherapy directly into the abdomen during surgery improves outcomes for people with advanced colon cancer that hasn't spread to other organs. It compares standard chemotherapy before surgery alone versus chemotherapy before surgery plus heated chemo during surgery.
Córdoba, CórdobaAges 18–75 - NCT05784688RecruitingPhase 1/Phase 2
TU2218 with Keytruda for advanced solid tumors
This trial studies TU2218 taken with Keytruda (pembrolizumab) in adults with advanced solid cancers that have limited treatment options. The goal is to see if the combination can shrink tumors and is safe enough to keep using.
San Antonio, TexasAges 18 years+ - NCT06024837Recruiting
Testing spectral CT for colorectal cancer spread to liver or belly
This study tests a new type of CT scan (spectral CT) to see how well it detects colorectal cancer that has spread to the liver or belly lining. It may help doctors better plan surgery to remove all the cancer.
Saint-EtienneAges Any age - NCT07003022RecruitingPhase 2
Two-drug combo for advanced colorectal cancer
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
Shanghai, ChinaAges 18–80 - NCT05197322RecruitingPhase 2
Pembrolizumab before surgery for MMR-deficient colon or rectal cancer
This trial tests pembrolizumab (an immunotherapy medicine) given before curative surgery in people with certain MMR-deficient colon or rectal cancers. It aims to shrink or control the cancer so surgery can be done more effectively, and to see if outcomes improve compared with standard care.
CambridgeAges 18 years+ - NCT06485713RecruitingPhase 2
Third-line therapy for advanced colorectal cancer
This trial tests a combination of two oral cancer drugs, trifluridine/tipiracil and fufuquitinib, as a third-line treatment for people with advanced colorectal cancer. It may be an option if prior treatments have stopped working.
Wenzhou, ZhejiangAges 18–75 - NCT06791512RecruitingPhase 3
Chemo Plus Targeted Therapy With or Without Immunotherapy for Colorectal Cancer
This trial compares a standard chemotherapy combination (mFOLFOX6) plus a targeted drug (bevacizumab) with or without an immunotherapy (PD-1 antibody) for locally advanced colorectal cancer. It aims to see if adding the immunotherapy improves outcomes for patients with a specific tumor type (pMMR/MSS).
Guangzhou, GuangdongAges 18–80 - NCT06946745Recruiting
Studying IBI363 combo for advanced colorectal cancer
This study tests a new combination therapy (IBI363 with other drugs) for advanced colorectal cancer that is pMMR/MSI-L/MSS. It aims to understand how the immune system around the tumor changes during treatment.
BeijingAges 18–75 - NCT06638502RecruitingPhase 1/Phase 2
Testing HRX215 for liver recovery after surgery
This trial tests a drug called HRX215 to see if it is safe and helps the liver recover after surgery to remove colon cancer tumors that have spread to the liver. It is for people who are having either a minor or major liver resection and have a low risk of liver failure.
Baltimore, MarylandAges 18–75 - NCT06751329RecruitingPhase 1/Phase 2
Study of DM002 for advanced solid tumors
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
Oklahoma City, OklahomaAges 18 years+ - NCT07082439RecruitingPhase 2
Pembrolizumab and Odetiglucan for Liver-Dominant Colorectal Cancer
This study tests a combination of two drugs, pembrolizumab and odetiglucan, in people whose colorectal cancer has spread mainly to the liver and has not responded to standard treatments. The goal is to see if this combination can shrink or slow the growth of liver tumors.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05947838Recruiting
Blood test helps choose chemotherapy before colorectal or appendix surgery
This study uses a blood test called ctDNA to help tailor (personalize) neoadjuvant chemotherapy for people with colorectal or appendix cancer before surgery. The goal is to see if using ctDNA can help doctors pick the most appropriate chemotherapy plan for you.
Houston, TexasAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT05969860RecruitingPhase 2
Home cancer treatment vs clinic treatment for advanced cancer
This Phase 2 trial compares giving certain standard cancer infusions at home versus in a clinic. It may help people avoid clinic visits while still receiving the same cancer treatment safely.
Jacksonville, FloridaAges 18 years+ - NCT05944237RecruitingPhase 1/Phase 2
Early trial for advanced cancers using HTL0039732
This is a Phase 1/2 study testing how well HTL0039732 works and is tolerated in people with advanced solid tumors that have not responded to standard treatments. It may help by offering a new treatment option and learning which cancer types and body markers respond best.
CambridgeAges 18 years+
Hear when a new Peritoneal Metastases From Colorectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for peritoneal metastases from colorectal cancer?
- Yes. Clin2 currently lists 63 recruiting peritoneal metastases from colorectal cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a peritoneal metastases from colorectal cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a peritoneal metastases from colorectal cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Liver Metastases From Colorectal Cancer
- Colorectal Cancer Liver Metastases (CRLM)
- Gastric Cancer Peritoneal Metastases
- Brain Metastases From Non-small Cell Lung Cancer (NSCLC)
- Brain Metastases From Breast Cancer
- Metastatic Colorectal Cancer
- Colorectal Cancer (CRC)
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.